Sensitive Quantification of Bulleyaconitine A in Human Serum by Liquid Chromatography-Tandem Mass Spectrometry

Injectable Erythrocyte Gel Loaded with Bulleyaconitine A for the Treatment of Rheumatoid Arthritis

“…Toxicity study is an important index to evaluate the safety of a material, and it has great significance for later clinical application. Excessive BLA has been reported to cause severe systemic side effects, such as ventricular arrhythmias, respiratory distress, and gastrointestinal reactions. − Due to the long-term duration for RA mice of BLA therapy, we conducted a toxicity study on day 63 post-treatment. In the present study, we demonstrated that weekly ankle injection of the BLA@RBCs (0.5 mg/kg) and intraperitoneal injection of BLA (0.05 mg/kg) had similar therapeutic effects on CIA mice.…”

“…In addition, the potential toxicity of BLA limits its wide application. It can be more harmful than beneficial with the high dosing or prolonged use of BLA, which possesses numerous side effects including sedation, respiratory distress, gastrointestinal reaction, and ventricular arrhythmias. − Therefore, we need to find novel delivery systems to modulate and reduce the local inflammatory responses …”

Activities of Naturally Occurring Alkaloids Bulleyaconitine A

“…With this method, only 0.2 mL serum is needed for analysis and it allows quantification of bulleyaconitine A ranging from 0.0587 to 11.7 ng/mL. [26] The quantification of bulleyaconitine A of 0.0587 ng/mL is reported to be sensitive enough to use for the pharmacokinetic study of intramuscularly injected bulleyaconitine A. However, this value was not sensitive enough for a pharmacokinetic study of orally administered bulleyaconitine A in human plasma.…”

Bulleyaconitine A prevents Ti particle‐induced osteolysis via suppressing NF‐κB signal pathway during osteoclastogenesis and osteoblastogenesis

“…Given the potential of natural compounds for the treatment of bone diseases, our group had screened a series of natural compounds and identified bulleyaconitine A (BLA) as a potential candidate. BLA is an active ingredient that is extracted from Aconitum bulleyanum plants and has curative effect in analgesia and anti-inflammation (Weng et al, 2005;Xiong, Zhai, & Yao, 2014). In addition, it has been used to treat chronic pain by blocking the voltage-dependent sodium channels (VGSCs) in state-dependent manner (Li, Fan, & Wang, 2016;Wang, Gerner, Wang, & Wang, 2007;) and stimulating dynorphin A to eliminate pain hypersensitivity and morphine tolerance in afferent neurons (Li, Wu, Wang, Li, & Wang, 2017).…”